Kiniksa Pharmaceuticals International, plc (KNSA)
NASDAQ: KNSA · Real-Time Price · USD
79.57
-3.60 (-4.33%)
Oct 21, 2026, 4:00 PM EDT - Market closed
KNSA Financials Overview
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 840.85 | 677.56 | 423.24 | 270.26 | 220.18 | 38.54 |
Revenue Growth | 58.85% | 60.09% | 56.61% | 22.75% | 471.24% | - |
Gross Profit Gross Profit Growth | 458.3 | 370.35 | 234.02 | 180.33 | 173.21 | 28.61 |
Operating Income Operating Income Growth | 100.25 | 77.22 | -45.62 | -25.2 | 9.77 | -156.64 |
Net Income Net Income Growth | 80.66 | 59.01 | -43.19 | 14.08 | 183.36 | -157.92 |
Earnings Per Share EPS Growth | 0.99 | 0.75 | -0.60 | 0.20 | 2.60 | -2.30 |
EPS Growth | 1399.63% | - | - | -92.31% | - | - |
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Product Revenue, Net Product Revenue, Net Growth | 840.85 | 677.56 | 417.03 | 233.18 | 122.52 | 38.54 |
License and Collaboration License and Collaboration Growth | - | - | 6.21 | 37.08 | 97.66 | - |
Revenue (Total) Revenue (Total) Growth | 840.85 | 677.56 | 423.24 | 270.26 | 220.18 | 38.54 |
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 525.93 | 414.07 | 243.63 | 206.37 | 190.61 | 182.2 |
Total Debt Total Debt Growth | 8.9 | 9.5 | 9.86 | 12.26 | 5.92 | 6.05 |
Net Cash (Debt) Net Cash Growth | 517.03 | 404.58 | 233.77 | 194.11 | 184.69 | 176.15 |
Net Cash Growth | 73.49% | 73.06% | 20.43% | 5.10% | 4.85% | -44.34% |
Net Cash Per Share Net Cash Per Share Growth | 6.31 | 5.12 | 3.27 | 2.70 | 2.62 | 2.57 |
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | 184.97 | 137.99 | 25.69 | 13.3 | 5.81 | -126.3 |
Capital Expenditures CapEx Growth | -2.13 | -1.57 | -0.28 | -0.13 | -0.11 | -0.42 |
Free Cash Flow Free Cash Flow Growth | 182.84 | 136.42 | 25.41 | 13.17 | 5.7 | -126.71 |
Free Cash Flow Growth | 174.98% | 436.82% | 92.94% | 130.99% | - | - |
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 54.50% | 54.66% | 55.29% | 66.72% | 78.67% | 74.22% |
Operating Margin | 11.92% | 11.40% | -10.78% | -9.32% | 4.44% | -406.38% |
Pretax Margin | 13.59% | 13.12% | -8.54% | -6.16% | 5.01% | -406.13% |
Profit Margin | 9.59% | 8.71% | -10.21% | 5.21% | 83.28% | -409.72% |
FCF Margin | 21.74% | 20.13% | 6.00% | 4.87% | 2.59% | -328.75% |
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Oct '26 Oct 21, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 80.35 | 52.99 | - | 87.60 | 5.68 | - |
Forward PE | 58.47 | 27.32 | 42.93 | 170.84 | 170.84 | - |
P/FCF Ratio | 33.96 | 22.92 | 56.20 | 93.67 | 182.67 | - |
PS Ratio | 7.38 | 4.61 | 3.37 | 4.57 | 4.73 | 21.04 |